Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Clinical Case Study: Efficacy of Dupilumab as a Steroid-Sparing Treatment for Refractory Anti-p200 Pemphigoid in a Patient with Multiple Comorbidities

  • By

  • Aikaterini Kyriakou

  • Christos Minas

  • Antonios Fantakis

  • Athanasia Tsaousi

  • Anastasia Tsitlakidou

  • Parthena Meltzanidou

  • Anthi-Maria Lazaridi

  • Alexandra Fleva

  • Anastasia Giannakou

  • Elisavet Lazaridou

  • Aikaterini Patsatsi

  • September 7, 2026

Share

Original Source(s)

Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities

  • by Aikaterini Kyriakou, Christos Minas, Antonios Fantakis, Athanasia Tsaousi, Anastasia Tsitlakidou, Parthena Meltzanidou, Anthi-Maria Lazaridi, Alexandra Fleva, Anastasia Giannakou, Elisavet Lazaridou, Aikaterini Patsatsi

  • September 7, 2026

Related Content

The Circadian Skin: Chronobiology as a New Frontier in Dermatological Therapy

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

What happens to clinical skills when AI does the routine work?

“The need to be extra vigilant when you're reviewing something versus doing it from scratch can be a real problem.”